Search

Your search keyword '"Cobimetinib -- Reports -- Forecasts and trends"' showing total 4 results
Start Over Descriptor "Cobimetinib -- Reports -- Forecasts and trends" Journal m2 presswire
4 results on '"Cobimetinib -- Reports -- Forecasts and trends"'

1. Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

Subjects
Merck KGaA -- Forecasts and trends, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, Novartis Pharma AG -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Eli Lilly and Co. -- Forecasts and trends, Brigatinib -- Forecasts and trends -- Reports, Osimertinib -- Forecasts and trends -- Reports, Cobimetinib -- Reports -- Forecasts and trends, Monoclonal antibodies -- Reports -- Forecasts and trends, Cancer research -- Reports -- Forecasts and trends, Pembrolizumab -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Romiplostim -- Reports -- Forecasts and trends, Non-small cell lung cancer -- Reports -- Forecasts and trends, Alectinib -- Forecasts and trends -- Reports, Durvalumab -- Reports -- Forecasts and trends, Nivolumab -- Reports -- Forecasts and trends, Small cell lung cancer -- Forecasts and trends -- Reports, Pharmaceutical industry -- Forecasts and trends, Antineoplastic agents -- Reports -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-July 15, 2020-: Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030 (C)1994-2020 M2 COMMUNICATIONS RDATE:14072020 DelveInsight's 'Non-Small [...]

Published
2020

2. Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast-2030

Subjects
Merck KGaA -- Forecasts and trends, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, Novartis Pharma AG -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Eli Lilly and Co. -- Forecasts and trends, Brigatinib -- Forecasts and trends -- Reports, Osimertinib -- Forecasts and trends -- Reports, Cobimetinib -- Reports -- Forecasts and trends, Monoclonal antibodies -- Reports -- Forecasts and trends, Romiplostim -- Reports -- Forecasts and trends, Pembrolizumab -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Non-small cell lung cancer -- Reports -- Forecasts and trends, Alectinib -- Forecasts and trends -- Reports, Durvalumab -- Reports -- Forecasts and trends, Nivolumab -- Reports -- Forecasts and trends, Small cell lung cancer -- Forecasts and trends -- Reports, Pharmaceutical industry -- Forecasts and trends, Antineoplastic agents -- Reports -- Forecasts and trends, Canakinumab, Necitumumab, Cabozantinib, Cemiplimab, Lorlatinib, Lung cancer, Avelumab, Trametinib, Vemurafenib, Larotrectinib, Dabrafenib, Atezolizumab, Binimetinib, Dacomitinib, Profits, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-May 20, 2020-: Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast-2030 (C)1994-2020 M2 COMMUNICATIONS RDATE:20052020 DelveInsight's 'Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast - [...]

Published
2020

3. Non-Small Cell Lung Cancer Pipeline Insight, Pipeline Assessment, Pipeline Drugs

Subjects
Merck KGaA -- Forecasts and trends, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, Novartis Pharma AG -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Eli Lilly and Co. -- Forecasts and trends, Brigatinib -- Forecasts and trends -- Reports, Business research -- Reports -- Forecasts and trends, Osimertinib -- Forecasts and trends -- Reports, Cobimetinib -- Reports -- Forecasts and trends, Monoclonal antibodies -- Reports -- Forecasts and trends, Medical research -- Reports -- Forecasts and trends, Pembrolizumab -- Forecasts and trends -- Reports, Romiplostim -- Reports -- Forecasts and trends, Non-small cell lung cancer -- Drug therapy, Alectinib -- Forecasts and trends -- Reports, Durvalumab -- Reports -- Forecasts and trends, Nivolumab -- Reports -- Forecasts and trends, Respiratory system agents -- Forecasts and trends -- Reports, Small cell lung cancer -- Drug therapy, Antineoplastic agents -- Reports -- Forecasts and trends, Canakinumab, Necitumumab, Cabozantinib, Diseases, Cemiplimab, Backup software, Lorlatinib, Lung cancer, Avelumab, Trametinib, Larotrectinib, Vemurafenib, Dabrafenib, Atezolizumab, Binimetinib, Dacomitinib, Drugs, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-April 29, 2020-: Non-Small Cell Lung Cancer Pipeline Insight, Pipeline Assessment, Pipeline Drugs (C)1994-2020 M2 COMMUNICATIONS RDATE:29042020 'Non-Small Cell Lung Cancer Pipeline Insight, 2020' report by DelveInsight outlays comprehensive [...]

Published
2020

4. Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies

Subjects
Merck KGaA -- Forecasts and trends -- Market research -- Market share, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends -- Market research -- Market share, Novartis Pharma AG -- Forecasts and trends -- Market research -- Market share, Pfizer Inc. -- Forecasts and trends -- Market research -- Market share, Eli Lilly and Co. -- Market research -- Forecasts and trends -- Market share, Brigatinib -- Market research -- Market share, Osimertinib -- Forecasts and trends -- Reports, Cobimetinib -- Reports -- Forecasts and trends, Monoclonal antibodies -- Reports -- Forecasts and trends, Market research -- Reports -- Forecasts and trends, Cancer research -- Reports -- Forecasts and trends, Pembrolizumab -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Romiplostim -- Market research -- Market share, Non-small cell lung cancer -- Reports -- Forecasts and trends, Alectinib -- Forecasts and trends -- Reports, Durvalumab -- Market research -- Market share, Nivolumab -- Reports -- Forecasts and trends, Small cell lung cancer -- Forecasts and trends -- Reports, Antineoplastic agents -- Market research -- Market share, Canakinumab, Necitumumab, Cabozantinib, Cemiplimab, Lorlatinib, Lung cancer, Avelumab, Trametinib, Larotrectinib, Vemurafenib, Dabrafenib, Atezolizumab, Binimetinib, Dacomitinib, Profits, Marketing research, Company market share, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-April 29, 2020-: Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies (C)1994-2020 M2 COMMUNICATIONS RDATE:29042020 LAS VEGAS - - The growth of NSCLC Market [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results